Black Diamond Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $70.0M | $0 | — | — | — |
| Research and development | $33.6M | $51.3M | $59.4M | $64.4M | $96.8M |
| Operating expenses | $57.5M | $78.8M | $86.5M | $92.8M | $126.9M |
| Operating income | $12.5M | -$78.8M | -$86.5M | -$92.8M | -$126.9M |
| Interest expense | — | — | — | — | $0 |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | $22.4M | -$69.7M | -$82.4M | -$91.2M | -$125.6M |
| Balance Sheet | |||||
| Cash and equivalents | $21.0M | $36.4M | $56.2M | $34.3M | $65.8M |
| Current assets | $132.4M | $101.2M | $134.0M | $127.7M | $215.7M |
| Total assets | $143.0M | $122.6M | $158.6M | $156.3M | $247.7M |
| Current liabilities | $15.7M | $20.6M | $19.6M | $15.3M | $23.6M |
| Total liabilities | $30.8M | $39.4M | $41.8M | $40.6M | $51.8M |
| Stockholders' equity | $112.2M | $83.3M | $116.7M | $115.7M | $195.9M |
| Cash Flow Statement | |||||
| Cash from operations | $29.6M | -$62.3M | -$66.7M | -$85.1M | -$100.1M |
| Depreciation and amortization | $325,000 | $343,000 | $437,000 | $508,000 | $205,000 |
| Stock-based compensation | $6.6M | $10.6M | $9.6M | $12.2M | $14.0M |
| Capital expenditure | — | $0 | $33,000 | $192,000 | $2.7M |
| Free cash flow | — | -$62.3M | -$66.8M | -$85.3M | -$102.9M |
| Impairments | $7.3M | $0 | — | — | — |
Shares outstanding 57.3M · Free float 65.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.